Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05075993 | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | active not recruiting | Phase 1 | 352 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | recruiting | Phase 1 | 70 | Context Therapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07441889 | HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02726997 | Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) | active not recruiting | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04495257 | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | completed | Phase 1 | 26 | Yale UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04886986 | Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 42 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641049 | Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer(DUAL-NK-PC) | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04167969 | The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06107868 | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer(GyneRep) | active not recruiting | Phase 1 | 6 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | recruiting | Phase 1 | 40 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07600554 | A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer(SWAP) | recruiting | Phase 1 | 20 | Philogen S.p.A.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations | recruiting | Phase 1 / Phase 2 | 178 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636707 | QLF4113 in Participants With Metastatic Prostate Cancer | not yet recruiting | Phase 1 | 140 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 9, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT05819892 | Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer | recruiting | Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05869123 | Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer | active not recruiting | Phase 1 / Phase 2 | 17 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05880485 | Online Adaptive Radiotherapy Cervical Cancer With Reduced Margin for Cervical Cancer | active not recruiting | Phase 1 / Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT07260162 | Evaluation of ATO-101™ in Patients With Non-Muscle-Invasive Bladder Cancer (PERSEVERANCE EU)(PERSEVERANCE) | not yet recruiting | Phase 1 | 24 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01171898 | Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 127 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04149145 | Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer(PARP) | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Jun 5, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01719926 | Phase I Platinum Based Chemotherapy Plus Indomethacin(PIFA) | completed | Phase 1 | 13 | UMC UtrechtOTHER | 2 | Jun 4, 2026 | clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT06609005 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 84 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT03873805 | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT05375539 | AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients | completed | Phase 1 | 12 | Milton S. Hershey Medical CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07198633 | A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07621692 | Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T | recruiting | Phase 1 | 12 | National Taiwan University HospitalOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04109729 | Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer(Rad2Nivo) | active not recruiting | Phase 1 | 39 | University of UtahOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05039801 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT07145177 | 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 | 30 | University of California, San FranciscoOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07344311 | A Phase I Trial of A-CAR032 in Participants With mCRPC | recruiting | Phase 1 | 27 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617753 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2(DUAL-OV-CAR-NK) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02048150 | Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT05200559 | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 25 | Alexander B Olawaiye, MDOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06533332 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 36 | EtiraRx Australia Pty LtdOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07567521 | A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC | recruiting | Phase 1 / Phase 2 | 90 | C Ray TherapeuticsINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 12, 2026source: clinicaltrials